课题基金 / 基金详情

Her2-targeted vectors for gene therapy of cancer

Her2-targeted vectors for gene therapy of cancer
用于癌症基因治疗的 Her2 靶向载体
批准号:
7586826
负责人:
VICTOR KRASNYKH
金额:
$32.21万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-07-18 至 2010-03-31

项目摘要

项目成果

VICTOR KRASNYKH的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The research proposed here will solve two major problems that currently limit the development of effective gene therapy for cancer: a lack of tumor-selective gene delivery by the gene vectors and inadequate means to monitor this process and its consequences. The first problem will be overcome through the development of a new class of tumor-specific adenovirus vectors whose natural tropism will be modified to target these agents to Her2, a recognized tumor marker. The work will have three major components, each drawing on the specific expertise of the Principal Investigator and Co-Investigators. First, a novel technology for designing proteins will be used to develop highly specific ligands that will bind to Her2 with high affinity. Importantly, this will be the first time these new molecules have been used in gene therapy in general and in vector design in particular. Next, two alternative targeting strategies will be used to genetically incorporate these ligands into the capsid of the adenovirus. After these vectors have been extensively characterized in vitro, they will be employed in tumor treatment studies in animals. This final aspect of the research proposed here will involve the extensive use of modern molecular imaging technology to monitor viral spread, as well as the efficacy and specificity of gene delivery. This work will result in the design of adenovirus vectors suitable for gene therapy that are truly targeted to a variety of Her2-expressing human tumors. The tumor selectivity, efficacy of gene delivery, and safety of these vectors will be greatly improved as a result. This developmental work will make future gene therapy interventions for cancer more efficient and safe, and elucidate their mechanisms of action and their consequences. The development of targeted Ad vectors proposed herein will thus be a major advance in cancer treatment. Moreover, such vectors would be of great utility in the wider field of gene therapy by serving as a prototype in the development of gene therapy for other diseases.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.jmb.2010.10.040
发表时间: 2011-01-14
期刊: Journal of molecular biology
影响因子: 5.6
作者: [Dreier B, Mikheeva G, Belousova N, Parizek P, Boczek E, Jelesarov I, Forrer P, Plückthun A, Krasnykh V]
通讯作者: Krasnykh V
DOI: 10.18632/oncotarget.10800
发表时间: 2016-08-16
期刊: Oncotarget
影响因子: --
作者: [Belousova N, Mikheeva G, Xiong C, Stagg LJ, Gagea M, Fox PS, Bassett RL, Ladbury JE, Braun MB, Stehle T, Li C, Krasnykh V]
通讯作者: Krasnykh V
Novel probes for near-infrared fluorescence imaging-guided oncologic surgery
New generation of radiotracers for PET imaging of molecular signatures of tumors
New generation of radiotracers for PET imaging of molecular signatures of tumors
Tumor-specific gene vectors for imaging and therapy of metastatic disease
海外基金